Trade Report: The Piper Jaffray Cos. Reiterates “$25.00” Price Target for Regenxbio Inc. (RGNX)

The Piper Jaffray Cos. Reiterates “$25.00” Price Target for Regenxbio Inc. (RGNX)

Piper Jaffray Cos. set a $25.00 price target on Regenxbio Inc. (NASDAQ:RGNX) in a research note issued to investors on Monday. The firm currently has a a buy rating on the stock.

A number of other research firms have also recently weighed in on RGNX. Chardan Capital reaffirmed a buy rating on shares of Regenxbio in a research report on Monday, August 22nd. Zacks Investment Research raised Regenxbio from a sell rating to a hold rating in a report on Friday, August 26th.

Shares of Regenxbio (NASDAQ:RGNX) opened at 16.75 on Monday. Regenxbio has a one year low of $7.07 and a one year high of $25.00. The stock’s market capitalization is $443.29 million. The firm has a 50-day moving average price of $14.26 and a 200 day moving average price of $11.36.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, equities analysts expect that Regenxbio will post ($2.37) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vivo Capital LLC purchased a new position in shares of Regenxbio during the first quarter worth $10,697,000. BlackRock Advisors LLC boosted its position in shares of Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock worth $5,501,000 after buying an additional 685,149 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Regenxbio by 1,004.9% in the second quarter. Franklin Resources Inc. now owns 700,500 shares of the company’s stock worth $5,604,000 after buying an additional 637,100 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Regenxbio by 178.5% in the second quarter. BlackRock Fund Advisors now owns 516,179 shares of the company’s stock worth $4,129,000 after buying an additional 330,862 shares during the last quarter. Finally, Janus Capital Management LLC boosted its position in shares of Regenxbio by 141.2% in the second quarter. Janus Capital Management LLC now owns 527,819 shares of the company’s stock worth $4,223,000 after buying an additional 308,956 shares during the last quarter. Hedge funds and other institutional investors own 68.73% of the company’s stock.

About Regenxbio

Related posts

Leave a Comment